Q1 2023 Earnings Estimate for Bluebird Bio, Inc. Issued By SVB Leerink (NASDAQ:BLUE)
Q1 2023 Earnings Estimate for Bluebird Bio, Inc. Issued By SVB Leerink (NASDAQ:BLUE)
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) – Equities researchers at SVB Leerink issued their Q1 2023 earnings per share estimates for shares of bluebird bio in a research report issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar anticipates that the biotechnology company will post earnings per share of ($0.64) for the quarter. SVB Leerink currently has a "Market Perform" rating and a $8.00 price objective on the stock. The consensus estimate for bluebird bio's current full-year earnings is ($4.36) per share. SVB Leerink also issued estimates for bluebird bio's Q2 2023 earnings at ($0.62) EPS and Q3 2023 earnings at ($0.58) EPS.
藍鳥生物公司(納斯達克：Blue-Get Rating)-SVB Leerink的股票研究人員在1月23日(星期一)發佈的一份研究報告中發佈了他們對藍鳥生物股票2023年第一季度每股收益的預期。SVB Leerink分析師M.Foroohar預計，這家生物技術公司將公佈本季度每股收益為0.64美元。SVB Leerink目前對該股的評級為“市場表現”，目標價為8美元。對藍鳥生物目前全年收益的普遍預期是每股4.36美元。SVB Leerink還發布了藍鳥生物2023年第二季度每股收益(0.62美元)和第三季度每股收益(0.58美元)的預期。
BLUE has been the subject of several other research reports. Morgan Stanley raised their target price on bluebird bio from $3.00 to $4.00 and gave the stock an "underweight" rating in a research report on Tuesday. Royal Bank of Canada cut their target price on bluebird bio to $8.00 and set a "sector perform" rating for the company in a research report on Tuesday, November 8th. Finally, StockNews.com initiated coverage on bluebird bio in a research report on Wednesday, October 12th. They set a "sell" rating for the company. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $6.75.
藍色一直是其他幾份研究報告的主題。摩根士丹利在週二的一份研究報告中將藍鳥生物的目標價從3.00美元上調至4.00美元，並給予該股“減持”評級。11月8日，加拿大皇家銀行在一份週二的研究報告中將藍鳥生物的目標價下調至8.00美元，併為該公司設定了“行業表現”評級。最後，StockNews.com在10月12日星期三的一份研究報告中開始了對藍鳥生物的報道。他們為該公司設定了“賣出”評級。三位投資分析師對該股的評級為賣出，六位分析師給出了持有評級，一位分析師給出了買入評級。根據MarketBeat，該公司目前的平均評級為持有，平均目標價為6.75美元。
bluebird bio Trading Up 5.5 %
藍鳥生物交易上漲5.5%
bluebird bio (NASDAQ:BLUE – Get Rating) last announced its quarterly earnings data on Monday, November 7th. The biotechnology company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.36. bluebird bio had a negative return on equity of 173.58% and a negative net margin of 8,828.28%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $2.25 million.
青鳥生物(納斯達克：Blue-Get Rating)上一次公佈季度收益數據是在11月7日星期一。這家生物技術公司公佈了該季度每股收益(0.92美元)，比分析師普遍預期的(1.28美元)高出0.36美元。藍鳥生物的淨資產回報率為負173.58%，淨利潤率為負8,828.28%。該公司本季度營收為70萬美元，而市場普遍預期為225萬美元。
Insider Activity at bluebird bio
藍鳥生物的內幕活動
In related news, Director Nick Leschly sold 4,290 shares of the firm's stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $7.80, for a total transaction of $33,462.00. Following the completion of the sale, the director now directly owns 280,149 shares of the company's stock, valued at approximately $2,185,162.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 9,506 shares of company stock valued at $72,088 in the last three months. Corporate insiders own 2.20% of the company's stock.
在相關新聞中，董事尼克·萊施利在1月11日星期三的一次交易中出售了4,290股該公司股票。該股以7.8美元的平均價格出售，總成交金額為33,462.00美元。出售完成後，董事現在直接擁有280,149股公司股票，價值約2,185,162.20美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可在美國證券交易委員會網站。過去三個月，內部人士出售了9,506股公司股票，價值72,088美元。企業內部人士持有該公司2.20%的股份。
Institutional Investors Weigh In On bluebird bio
機構投資者參與藍鳥生物
Hedge funds and other institutional investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY increased its stake in shares of bluebird bio by 142.4% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company's stock valued at $30,000 after buying an additional 2,744 shares during the period. US Bancorp DE increased its stake in shares of bluebird bio by 234.9% in the 3rd quarter. US Bancorp DE now owns 7,918 shares of the biotechnology company's stock valued at $50,000 after buying an additional 5,554 shares during the period. Amalgamated Bank bought a new position in shares of bluebird bio in the 1st quarter worth $39,000. PEAK6 Investments LLC bought a new position in shares of bluebird bio in the 2nd quarter worth $41,000. Finally, Laurion Capital Management LP bought a new position in shares of bluebird bio in the 2nd quarter worth $42,000. 79.01% of the stock is owned by institutional investors and hedge funds.
對衝基金和其他機構投資者最近對他們在該公司的頭寸進行了調整。紐約大都會人壽保險公司在第三季度增持了藍鳥生物的股份142.4%。紐約大都會人壽保險公司現在持有這家生物技術公司4671股股票，價值3萬美元，在此期間又購買了2744股。美國Bancorp DE在第三季度增持了藍鳥生物的股份234.9%。US Bancorp DE現在持有這家生物技術公司7918股股票，價值5萬美元，在此期間又購買了5554股。合併銀行在第一季度購買了藍鳥生物的新頭寸，價值3.9萬美元。Peak6 Investments LLC在第二季度購買了藍鳥生物的新頭寸，價值41,000美元。最後，Laurion Capital Management LP在第二季度購買了藍鳥生物的新頭寸，價值42,000美元。79.01%的股票由機構投資者和對衝基金持有。
About bluebird bio
關於藍鳥傳記
(Get Rating)
(獲取評級)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
藍鳥生物公司是一家生物技術公司，研究、開發和商業化針對嚴重遺傳病的變革性基因療法。其用於治療嚴重遺傳性疾病的候選產品包括用於治療輸血依賴型β-地中海貧血的貝替貝吉基因Autotemcel；用於治療鐮狀細胞病(SCD)的lovotieglogene autemcel；以及用於治療大腦腎上腺腦白質營養不良的伊利伐多烯Autotemcel。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
- 免費獲取StockNews.com關於藍鳥生物的研究報告(藍色)
- 高收益、高價值的Verizon陷入谷底
- 科蒂股票能否在2023年出現上行
- 你應該用這隻反向ETF做空納斯達克100指數嗎？
- 業內人士買入阿徹航空，這隻股票要起飛了嗎？
- Intuit即將採取行動，但走哪條路呢？
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
獲得藍鳥生物日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對藍鳥生物和相關公司的最新新聞和分析師評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。